ArticleInternational journal of clinical pharmacy2026
Risk factor analysis of hypertonic saline non-responders for the treatment of cerebral edema: a retrospective cohort study.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFirst line treatment of cerebral edema or elevated intracranial pressure involves hyperosmolar therapy.
aimThe purpose of this study was to identify risk factors associated with hypertonic saline solutions (HTS) non-responders post HTS bolus for treatment of cerebral edema.
methodThis single center, retrospective cohort study included neurocritical care patients who received one bolus dose of 3% NaCl (> 100 mL) or 23.4% NaCl (30 mL) and obtained one serum sodium level between one and eight hours after administration. The primary outcome was to determine the incidence of HTS non-responders, defined as a serum sodium response of < 5 mEq/L on repeat lab draw, and to identify risk factors associated with HTS non-response (sodium < 5 mEq/L) within 8 h after a HTS bolus dose.
resultsA total of 200 patients were included. The primary neurologic injuries included were acute ischemic stroke (41.5%) and intracerebral hemorrhage (35.5%). For the primary outcome, 127 (63.5%) patients were HTS non-responders. Risk factors associated with HTS non-response, included patients who did not receive mannitol prior to HTS (OR 3.31, 95% CI 1.34-8.17; p = 0.009), male sex (OR 2.43; 95% CI 1.27-4.63; p = 0.007), and patients without intraventricular hemorrhage (IVH) (OR 2.12; 95% CI 1.11-4.06; p = 0.024).
conclusionOverall, 63.5% patients were non-responders to HTS. Risk factors for non-response to HTS included no prior mannitol therapy, male sex, and patients without IVH. Further studies are warranted to assess the impact these risk factors have on HTS dosing and the treatment of cerebral edema.
Indexed as
Identifiers
41379290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.